Connect
MJA
MJA

The PBS community awareness campaign: how helpful is blaming patients?

Evan Doran and David A Henry
Med J Aust 2003; 179 (10): . || doi: 10.5694/j.1326-5377.2003.tb05682.x
Published online: 17 November 2003

The current “Pharmaceutical Benefits Scheme (PBS) community awareness campaign” explicitly links the difficulties facing the PBS to patient behaviour and “waste”. The campaign suggests that patients are taking advantage of affordable access to prescription medicines, and emphasises that patient responsibility is “the prescription for a healthy PBS”. By neglecting to inform the public that the pressures facing the PBS also include doctors’ prescribing habits and intensive pharmaceutical industry marketing, the campaign has missed an opportunity to initiate a balanced and constructive debate about the future viability of the PBS.

It has become something of an axiom that increasing cost is endangering the Pharmaceutical Benefits Scheme (PBS), and that something must be done about it. Typically, policy responses have been to target the prescription end-user — the patient. Successive governments have increased patients’ out-of-pocket charges as a means of containing drug costs. The present federal Government, thwarted thus far by the Senate in its attempt to increase the patient co-payment, is trying an alternative — appealing to patients’ moral sensibilities rather than their hip-pocket nerve.


  • Discipline of Clinical Pharmacology, University of Newcastle, Newcastle, NSW.


Correspondence: 

Competing interests:

None identified.

  • 1. Australian Government Department of Health and Ageing. PBS community awareness campaign. Available at: www.health.gov.au/pbs/general/campaign.htm (accessed Oct 2003).
  • 2. Australian Government Department of Health and Ageing. The National Strategy for Quality Use of Medicines. Canberra, ADHA, 2002. Available at: www.nmp.health.gov.au/quality.htm (accessed Oct 2003).
  • 3. Parliamentary debates. Australian House of Representatives. 40th Parliament, 1st Session—6th Period. Official Hansard, No. 14, 2003: 20527. Available at: www.aph.gov.au/hansard/reps/dailys/dr180903.pdf (accessed Oct 2003).
  • 4. Davey P, Lees M, Aristides M. Report on the Australian System of Pharmaceutical Financing and Delivery. Vol 1: Efficiency and equity implications of public versus private funding of pharmaceuticals. Chatswood, NSW: Medical Technology Assessment Group, Nov 1999.
  • 5. Gerdtham U-G, Johannesson M. The impact of user charges on the consumption of drugs. Pharmacoeconomics 1996; 9: 478-483.
  • 6. McManus P, Donnelly N, Henry DA, et al. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996; 5: 385-392.
  • 7. Stuart B, Grana J. Ability to pay and the decision to medicate. Med Care 1998; 36: 202-211.
  • 8. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
  • 9. Richardson J. The effects of consumer co-payments in medical care. National Health Strategy Unit, June 1991. (National Health Strategy Background Paper No. 5.) Available at: www.health.gov.au/archive/nhs/documents/nhs6.pdf (accessed Oct 2003).
  • 10. Kerr SJ, Mant A, Horn FE, et al. Lessons from early large-scale adoption of celecoxib and rofecoxib by general practitioners. Med J Aust 2003; 179: 403-407. <MJA full text>
  • 11. Dowden JS. Coax, COX and cola [editorial]. Med J Aust 2003; 179: 397-398. <MJA full text>
  • 12. Hill SR, Henry DA, Smith AJ. Rising prescription drug costs: whose responsibility? [editorial] Med J Aust 1997; 167: 6-7.
  • 13. Rickard M. The Pharmaceutical Benefits Scheme: options for cost control. Canberra: Parliament of Australia, Department of the Parliamentary Library, 2002. (Current Issues Brief No. 12, 2001–02.)
  • 14. Young AF, Dobson AJ. The decline in bulk-billing and increase in out-of-pocket costs for general practice consultations in rural areas of Australia, 1995–2001. Med J Aust 2003; 178: 122-126. <MJA full text>
  • 15. Consumers’ Health Forum. Costs of chronic illness and Quality Use of Medicine. Lyons, ACT: Consumers’ Health Forum of Australia Inc, 1997.
  • 16. Nelkin D. An uneasy relationship: the tensions between medicine and the media. Lancet 1996; 347: 1600-1603.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.